p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11)

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 699-705

  Wierdl, Monika ^a   Morton, Christopher L ^a   Harris, Linda C ^a   Danks, Mary K ^a   Schuetz, John D ^a   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; IRINOTECAN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG SENSITIZATION; ENZYME REGULATION; ENZYME THERAPY; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RABBIT; ROUS SARCOMA ONCOVIRUS; VIRAL DIRECTED ENZYME PRODRUG THERAPY; VIRUS CELL INTERACTION; WILD TYPE;

ANIMALS; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; RABBITS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037310740     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044149     Document Type: Article

References (23)

1. Baker SJ, Markowitz S, Fearon ER, Willson JK, and Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Wash DC) 249:912-915.
2. Beaufay H, Amar-Costesec A, Feytmans E, Thines-Sempoux D, Wibo M, Robbi M, and Berthet J (1974) Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J Cell Biol 61:188-200.
3. Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, Pawlik CA, Houghton PJ, and Potter PM (1999) Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 5:917-924.
4. Danks MK, Morton CL, Pawlik CA, and Potter PM (1998) Overexpression of a rabbit liver caxboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 58:20-22.
5. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, and Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1:45-49.
6. Habib NA, Hodgson HJ, Lemoine N, and Pignatelli M (1999) A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Therapy 10:2019-2034.
7. Harris LC, Remack JS, Houghton PJ, and Brent TP (1996) Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res 56:2029-2032.
8. Levine A (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
9. Levine A, Momand J, and Finley C (1991) The p53 tumor suppressor gene. Nature (Lond) 351:453-455.
10. McPake CR, Shetty S, Kitchingman GR, and Harris LC (1999) Wild-type p53 induction mediated by replication-deficient adenoviral vectors. Cancer Res 59:4247-4251.
11. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, and George DL (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13:2490-2501.
12. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, et al. (2000) Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18:609-622.
13. Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, and Chin KV (1994) Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71-77.
14. Potter PM, Pawlik CA, Morton CL, Naeve CW, and Danks MK (1998a) Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug Irinotecan (CPT-11). Cancer Res 52:2646-2651.
15. Potter PM, Wolverton JS, Morton CL, Wierdl M, and Danks MK (1998b) Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res 58:3627-3632.
16. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, and Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276:39359-39367.
17. Santhanam U, Ray A, and Sehgal PB (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88:7605-7609.
18. Subler MA, Martin DW, and Deb S (1992) Inhibition of viral and cellular promoters by human wild-type p53. J Virol 66:4757-4762.
19. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, and Schuetz JD (1997) p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci 94:11037-11042.
20. Wang P, Reed M, Wang Y, Mayr G, Stenger JE, Anderson ME, Schwedes JF, and Tegtmeyer P (1994) p53 domains: structure, oligomerization and transformation. Mol Cell Biol 14:5182-5191.
21. Wang Q and Beck WT (1998) Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58:5762-5769.
22. Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, and Potter PM (2001) Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 61:5078-5082.
23. Zambetti GP and Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855-865.